Influence of thalidomide on VEGF,bFGF and TNF-αof patients with advanced non-small cell lung cancer
10.7619/jcmp.201417013
- VernacularTitle:沙利度胺对晚期NSCLC血清VEGF、bFGF和TNF-α的影响
- Author:
Chunhui YE
1
;
Zili MENG
Author Information
1. 南京医科大学附属淮安第一医院 呼吸科
- Keywords:
thalidomide;
chemotherapy;
non-small cell lung cancer;
vascular endothelial growth factor
- From:
Journal of Clinical Medicine in Practice
2014;(17):44-46,51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of thalidomide combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)and its influence on vascular endothe-lial growth factor (VEGF),basic fibroblast growth factor (bFGF)and tumor necrosis factor-α(TNF-α).Methods A total of 87 patients with advanced NSCLC were enrolled and randomly divided into observational group (45 cases)and control group (42 cases).Patients in control group received NP regimen while patients in observational group received thalidomide +NP regimen.The clinical effica-cy and the changes of the levels of VEGF,bFGF and TNF-αwere observed.Results Clinical benefit rate (CBR)of observational group was significantly higher than control group (P<0.01).Compared with treatment before,the levels of VEGF in 2 groups decreased significantly (P<0.05)and the lev-els of bFGF in observational group reduced obviously (P<0.05 )but there was no significant differ-ence between treatment before and after treatment (P>0.05).The level of TNF-αafter treatment in 2 groups was obviously lower than treatment before (P<0.05,or P<0.01 )and observational group was significantly lower than control group (P <0.05 ).Conclusion Thalidomide combined with chemotherapy can reduce the level of VEGF,bFGF and TNF-αin the treatment of advanced NSCLC.
